The effects of continuous positive airway pressure and mandibular advancement therapy on metabolic outcomes of patients with mild obstructive sleep apnea: a randomized controlled study

Background Moderate and severe obstructive sleep apnea (OSA) have been independently associated with dyslipidemia. The results of metabolic improvement with continuous positive airway pressure (CPAP) have been controversial. Less evidence exists regarding this issue in mild OSA. A current treatment for mild OSA is mandibular advancement device (MAD) therapy, but its effectiveness on the metabolic profile needs to be compared with CPAP. The purpose of this study was to compare MAD vs CPAP vs no treatment on the metabolic profile during 6 and 12 months of follow-up in patients with mild OSA. Methods The inclusion criteria were patients with mild OSA, both genders, ages 18 to 65 years, and body mass index (BMI) of < 35 Kg/m(2). Patients were randomized in 3 groups (CPAP, MAD, and control). The evaluations included physical examination, metabolic profile, and full polysomnography at baseline, 6 months, and 12 months of follow-up. Results Seventy-nine patients with mild OSA were randomized in three treatment groups, with mean age (+/- SD) of 47 +/- 9 years, 54% men, and AHI 9.5 +/- 2.9 events/h. MAD and CPAP reduced AHI at 6 and 12 months compared to the control group. MAD adherence was higher than CPAP at 6 and 12 months. Despite lower adherence compared to MAD, CPAP was more effective in reducing total cholesterol over 12 months (baseline 189.3 +/- 60.2 mg/dl to 173.4 +/- 74.3 mg/dl) and low-density lipoprotein cholesterol (LDL-c, baseline 112.8 +/- 54.9 mg/dl to 94.5 +/- 67.4 mg/dl). Conclusions After 1 year of treatment, CPAP was superior to MAD in reducing total cholesterol and LDL-c in patients with mild OSA.

Automated summary

This study compared the effects of MAD and CPAP on the metabolic profile in patients with mild OSA. After 1 year of treatment, CPAP was found to be superior to MAD in reducing total cholesterol and low-density lipoprotein cholesterol levels.